Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Clinical Trial ID NCT01668784

PubWeight™ 69.88‹?›

🔗 Visit the page for NCT01668784

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015 12.74
2 Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014 9.86
3 Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013 4.78
4 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
5 Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 2014 2.78
6 Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2013 2.64
7 Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol 2015 2.30
8 The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry. Cancer Prev Res (Phila) 2015 2.17
9 Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013 1.41
10 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
11 Immune modulation for cancer therapy. Br J Cancer 2014 1.15
12 Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol 2016 1.14
13 Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016 1.12
14 New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med 2015 1.12
15 A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 2013 1.12
16 Adjuvant therapy for renal cell carcinoma: past, present, and future. Oncologist 2014 1.11
17 Renal cell carcinoma: molecular biology and targeted therapy. Curr Opin Oncol 2014 1.01
18 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
19 Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J Urol 2013 0.98
20 Immune checkpoint inhibitors in clinical trials. Chin J Cancer 2014 0.98
21 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
22 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
23 Targeted therapy for renal cell carcinoma: The next lap. J Carcinog 2014 0.89
24 Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 2015 0.88
25 Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. Cancer J 2014 0.88
26 Immunologics and chemotherapeutics for renal cell carcinoma. Semin Intervent Radiol 2014 0.85
27 PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther 2014 0.85
28 PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunol Res 2014 0.85
29 Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review. Biomed Res Int 2015 0.83
30 Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma. Hum Vaccin Immunother 2015 0.83
31 Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience. BJU Int 2015 0.81
32 The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist 2015 0.81
33 Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 2015 0.79
34 Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting. Urol Oncol 2015 0.78
35 Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. Oncoimmunology 2015 0.77
36 Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology 2015 0.77
37 Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma. ESMO Open 2016 0.77
38 An update on current management of advanced renal cell cancer, biomarkers, and future directions. Ann Cancer Res 2015 0.76
39 Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. BioDrugs 2014 0.76
40 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
41 Individualising treatment choices in a crowded treatment algorithm. EJC Suppl 2013 0.75
42 Third-line treatment in metastatic renal cell carcinoma and bone metastases. Can Urol Assoc J 2015 0.75
43 Metastatic clear cell renal carcinoma - an unusual response to Temsirolimus in second line therapy. J Med Life 2016 0.75
44 A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma. Clin Cancer Res 2015 0.75
45 Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer 2016 0.75
46 Does a reasonable treatment approach beyond second-line exist? EJC Suppl 2013 0.75
Next 100